After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firm

The past four years at Bristol Myers Squibb have been busy for Matthew Roden. The senior VP and head of enterprise strategy was behind the company’s initial plan following its major $74 billion Celgene buyout last year. But now, it’s on to greener pastures.

Roden’s been tapped as executive partner at Cambridge, MA-based venture capital firm MPM Capital —  a move he said has always been part of his long-term goals.

“Going into venture capital was part of my long-term plan … and it did happen a little bit faster than I expected. But certain opportunities have opened up over the past year. And … MPM specifically, I’ve always had a huge respect for their track record and for the people there,” Roden told Endpoints News.

Roden, a self-described “science nerd,” said he knew early on in graduate school that he wanted to marry his interests in capital markets, science and technology. In 2005, he joined Credit Suisse as an associate analyst, where he worked for a year before becoming vice president at JP Morgan. Then in 2010, he jumped to the Swiss investment banking firm UBS as biotech equity research sector head.

On the BMS R&D leadership team representing external innovation, Roden led teams on more than 100 business development transactions, including the Celgene acquisition, which gave the company late-stage candidates like immunology and inflammation drugs TYK2 and ozanimod.

“You know I accomplished a lot in a relatively short period of time at BMS, which made it possible to … accelerate my long-term plan of moving to venture,” he said.

At MPM, Roden will be responsible for identifying and assessing new technologies and advising portfolio executives on business and clinical strategies.

“I want to be part of building great biotech companies — the next wave innovators,” he said.

“Matt’s experience and success as a biopharmaceutical executive, a biotech equity research analyst, and a scientist bring a trifecta of unique and valuable insight to our investment team and the MPM portfolio,” Ansbert Gadicke, MPM co-founder and managing director, said in a statement.

Click to view original post